The Society for Functional Precision Medicine
@thesfpm.bsky.social
Our mission is to improve patient care by advancing functional precision medicine through research, education, clinical implementation, and collaboration with academia, industry, regulators, and patients.
Join us: https://www.sfpm.io/
Join us: https://www.sfpm.io/
Reposted by The Society for Functional Precision Medicine
𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
The Society for Functional Precision Medicine - Login
The Society for Functional Precision Medicine
sfpm.membershiptoolkit.com
November 11, 2025 at 11:35 AM
𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
The Society for Functional Precision Medicine - Login
The Society for Functional Precision Medicine
sfpm.membershiptoolkit.com
November 11, 2025 at 11:35 AM
𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
✅ Vote now: sfpm.membershiptoolkit.com
🚨Excited to announce the seminar by Kushtrim Kryeziu, PhD (Oslo University) on "Functional Precision Oncology for Metastatic Colorectal Cancer". Join us TODAY, at 12 PM EDT, open to everyone! Don't miss it and consider joining the SFPM
www.sfpm.io/seminars
www.sfpm.io/seminars
Seminars | SFPM
The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
www.sfpm.io
October 8, 2025 at 11:10 AM
🚨Excited to announce the seminar by Kushtrim Kryeziu, PhD (Oslo University) on "Functional Precision Oncology for Metastatic Colorectal Cancer". Join us TODAY, at 12 PM EDT, open to everyone! Don't miss it and consider joining the SFPM
www.sfpm.io/seminars
www.sfpm.io/seminars
Reposted by The Society for Functional Precision Medicine
What incredible news today. I feel so grateful to have worked closely with Tony over the years and to have witnessed firsthand his vision, energy, and commitment to advancing functional precision medicine. I cannot think of a steadier (and more needed) force at the NCI at this time /n
We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine 🧵
www.nih.gov/news-events/...
www.nih.gov/news-events/...
Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute
Dr. Letai will serve as NCI’s 18th director.
www.nih.gov
September 29, 2025 at 10:04 PM
What incredible news today. I feel so grateful to have worked closely with Tony over the years and to have witnessed firsthand his vision, energy, and commitment to advancing functional precision medicine. I cannot think of a steadier (and more needed) force at the NCI at this time /n
We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine 🧵
www.nih.gov/news-events/...
www.nih.gov/news-events/...
Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute
Dr. Letai will serve as NCI’s 18th director.
www.nih.gov
September 29, 2025 at 10:00 PM
We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine 🧵
www.nih.gov/news-events/...
www.nih.gov/news-events/...
We were honored to host Jens M. Kelm, PhD (PreComb Therapeutics) for our September seminar.
Dr. Kelm shared insights on:
🎯 Dynamic Drug Response Profiling at Scale for Functional Precision Oncology
If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...
Dr. Kelm shared insights on:
🎯 Dynamic Drug Response Profiling at Scale for Functional Precision Oncology
If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...
www.youtube.com
September 17, 2025 at 9:50 AM
We were honored to host Jens M. Kelm, PhD (PreComb Therapeutics) for our September seminar.
Dr. Kelm shared insights on:
🎯 Dynamic Drug Response Profiling at Scale for Functional Precision Oncology
If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...
Dr. Kelm shared insights on:
🎯 Dynamic Drug Response Profiling at Scale for Functional Precision Oncology
If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...
✨ Excited to announce a talk by Jens M. Kelm, PhD (Founder and CSO PreComb Therapeutics AG) on "Dynamic Drug Response Profiling at Scale for Functional Precision Oncology", Join us next Wednesday, September 10, 2025, at 12 PM EDT. Don't miss it!
www.sfpm.io/seminars
www.sfpm.io/seminars
Seminars | SFPM
The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
www.sfpm.io
September 8, 2025 at 6:10 PM
✨ Excited to announce a talk by Jens M. Kelm, PhD (Founder and CSO PreComb Therapeutics AG) on "Dynamic Drug Response Profiling at Scale for Functional Precision Oncology", Join us next Wednesday, September 10, 2025, at 12 PM EDT. Don't miss it!
www.sfpm.io/seminars
www.sfpm.io/seminars
Join us this Wednesday 06/11 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Chris Steffi from CompagOs will discuss: "Pioneering Solutions to Understand, Diagnose and Treat Bone Conditions"
More info & link to join: www.sfpm.io/seminars
More info & link to join: www.sfpm.io/seminars
Seminars | SFPM
The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
www.sfpm.io
June 10, 2025 at 6:20 AM
Join us this Wednesday 06/11 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Chris Steffi from CompagOs will discuss: "Pioneering Solutions to Understand, Diagnose and Treat Bone Conditions"
More info & link to join: www.sfpm.io/seminars
More info & link to join: www.sfpm.io/seminars
Precision approaches to tackle acquired resistance to cancer, including model-based functional strategies:
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer
Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...
www.nature.com
June 3, 2025 at 4:37 PM
Precision approaches to tackle acquired resistance to cancer, including model-based functional strategies:
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by The Society for Functional Precision Medicine
In panel discussion on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics. Chair Tony Letai. #AACRprecmed25 🧪🧬🖥️
March 12, 2025 at 5:17 PM
In panel discussion on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics. Chair Tony Letai. #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
Now: Peter Horak. #AACRprecmed25 🧪🧬🖥️
March 12, 2025 at 5:23 PM
Now: Peter Horak. #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
Now: Keith Ligon. #AACRprecmed25 🧪🧬🖥️
March 12, 2025 at 5:25 PM
Now: Keith Ligon. #AACRprecmed25 🧪🧬🖥️
Two of our Board members, Dr. Letai and Dr. Ligon, are part of this #AACRPM25 panel focused on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics
March 12, 2025 at 5:30 PM
Two of our Board members, Dr. Letai and Dr. Ligon, are part of this #AACRPM25 panel focused on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics
Join us *today* Wednesday 03/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources"
More info: www.sfpm.io/seminars
Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources"
More info: www.sfpm.io/seminars
Seminars | SFPM
The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
www.sfpm.io
March 12, 2025 at 1:18 PM
Join us *today* Wednesday 03/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources"
More info: www.sfpm.io/seminars
Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources"
More info: www.sfpm.io/seminars
Reposted by The Society for Functional Precision Medicine
Now: Keith Flaherty: Targets and therapeutics in need of functional insights to guide drug development in solid tumors #AACRprecmed25 🧪🧬🖥️
March 11, 2025 at 9:13 PM
Now: Keith Flaherty: Targets and therapeutics in need of functional insights to guide drug development in solid tumors #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
Continued 2: KF: Genetic evidence points to multiple resistance pathways #AACRprecmed25 🧪🧬🖥️ https://aacrjournals.org/clincancerres/article/24/24/6195/15360/Landscape-of-EGFR-Dependent-and-Independent
March 11, 2025 at 9:30 PM
Continued 2: KF: Genetic evidence points to multiple resistance pathways #AACRprecmed25 🧪🧬🖥️ https://aacrjournals.org/clincancerres/article/24/24/6195/15360/Landscape-of-EGFR-Dependent-and-Independent
Reposted by The Society for Functional Precision Medicine
Now: Jeffrey Tyner: Functional omics for novel therapeutic combinations in myeloid malignancies #AACRprecmed25 🧪🧬🖥️
March 11, 2025 at 10:02 PM
Now: Jeffrey Tyner: Functional omics for novel therapeutic combinations in myeloid malignancies #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
Continued 2: JT: Experimental approach: primary cells -> overnight exposure -> CITE-seq: dynamic changes and cell persistence under therapeutic selective pressure. With @wondermixtape.bsky.social #AACRprecmed25 🧪🧬🖥️
March 11, 2025 at 10:31 PM
Continued 2: JT: Experimental approach: primary cells -> overnight exposure -> CITE-seq: dynamic changes and cell persistence under therapeutic selective pressure. With @wondermixtape.bsky.social #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
Now: Coleman Lindsley: Dyanmic assessment in leukemia. What is minimal residual disease and does it matter? #AACRprecmed25 🧪🧬🖥️
March 11, 2025 at 10:55 PM
Now: Coleman Lindsley: Dyanmic assessment in leukemia. What is minimal residual disease and does it matter? #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
Now: Sascha Dietrich: Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies #AACRprecmed25 🧪🧬🖥️
March 11, 2025 at 11:27 PM
Now: Sascha Dietrich: Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies #AACRprecmed25 🧪🧬🖥️
Reposted by The Society for Functional Precision Medicine
On my way to @theaacr.bsky.social special conference in cancer research: functional and genomic precision medicine in cancer. Who else will be there? @alice.soragnilab.com #AACRprecmed25 www.aacr.org/meeting/aacr...
AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
www.aacr.org
March 11, 2025 at 7:44 PM
On my way to @theaacr.bsky.social special conference in cancer research: functional and genomic precision medicine in cancer. Who else will be there? @alice.soragnilab.com #AACRprecmed25 www.aacr.org/meeting/aacr...
Reposted by The Society for Functional Precision Medicine
This first AACR meeting on functional and genomic precision medicine has officially started! Dr. Mardis gave the introductory remarks followed by our first plenary speaker, Dr. Flaherty, who will focus on the collision of genomic and functional precision medicine #AACRPM25
March 11, 2025 at 9:15 PM
This first AACR meeting on functional and genomic precision medicine has officially started! Dr. Mardis gave the introductory remarks followed by our first plenary speaker, Dr. Flaherty, who will focus on the collision of genomic and functional precision medicine #AACRPM25
Reposted by The Society for Functional Precision Medicine
Do not miss this great talk tomorrow at 5pm CET (12pm EDT): Zinaida Perova (EMBL) "Leveraging CancerModels.Org: Enhancing Precision Oncology Through Collaborative Cancer Model Resources". @thesfpm.bsky.social
www.sfpm.io/seminars
www.sfpm.io/seminars
March 11, 2025 at 11:14 AM
Do not miss this great talk tomorrow at 5pm CET (12pm EDT): Zinaida Perova (EMBL) "Leveraging CancerModels.Org: Enhancing Precision Oncology Through Collaborative Cancer Model Resources". @thesfpm.bsky.social
www.sfpm.io/seminars
www.sfpm.io/seminars
Join us *today* Wednesday 02/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors.
More info: www.sfpm.io/seminars
Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors.
More info: www.sfpm.io/seminars
February 12, 2025 at 3:29 PM
Join us *today* Wednesday 02/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors.
More info: www.sfpm.io/seminars
Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors.
More info: www.sfpm.io/seminars
An exciting multicenter phase 2 functional precision medicine clinical trial showing how a rapid ex vivo venetoclax sensitivity assay was the strongest predictor for a favorable treatment response and survival in relapsed/refractory secondary AML
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial
Key PointsBlast-specific ex vivo venetoclax sensitivity correlated strongly with treatment responses and predicted longer survival.VenEx trial showed that
ashpublications.org
January 29, 2025 at 6:45 AM
An exciting multicenter phase 2 functional precision medicine clinical trial showing how a rapid ex vivo venetoclax sensitivity assay was the strongest predictor for a favorable treatment response and survival in relapsed/refractory secondary AML
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...